Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1347 • ACR Convergence 2023
Continuing Biologic DMARDs During Pregnancy in Women with Rheumatic Disease Was Not Associated with Increased Unfavorable Pregnancy Outcomes, Serious Infections, and Adverse Effects of Vaccination
Hiromi Shimada¹, Risa Wakiya², Shusaku Nakashima², Taichi Miyagi³, Yusuke Ushio⁴, Koichi Sugihara⁵, Rina Mino⁶, Mao Mizusaki², Kanako Chujo⁷, Ryoko Kagawa⁴, Hayamasa Yamaguchi⁴, Tomohiro Kameda² and Hiroaki Dobashi², ¹Kagawa University, Kagawa, Japan, ²Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan, ³Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kidagun, Japan, ⁴Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan, ⁵Kagawa University, Miki-cho, Kita-gun, Japan, ⁶Kagawa University, Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan, ⁷Kagawa University, Miki, Kita District, Kagawa, Japan
Background/Purpose: It is important to control disease activity during pregnancy in women with rheumatic diseases because its exacerbation is associated with increased adverse pregnancy outcomes.…
Abstract Number: 1676 • ACR Convergence 2023
Tofacitinib Accelerates in Vitro Clot Formation and Delays Clot Lysis in Rheumatoid Arthritis Blood by Enhancement of Macrophage TLR4 Mediated Cytokine Responses- a New Angle on Thrombosis with JAKi in Rheumatology
Paula David¹, Thomas Macleod², Yu Shi³, Payal Ganguly¹, Cedric Duval³, Mark Harland¹, Chi Wong¹, Benazir Saleem⁴ and Dennis McGonagle⁵, ¹University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), Leeds, United Kingdom, ²University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ³Discovery and Translational Science Department, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom, ⁴Leeds Teaching Hospitals NHS Trust, Rheumatology, Chapel Allerton Hospital, Leeds, United Kingdom, ⁵Leeds Biomedical Research Centre, University of Leeds, Leeds, United Kingdom
Background/Purpose: Rheumatoid Arthritis (RA) patients treated with Janus Kinase inhibitors (JAKi) have reportedly higher venous thromboembolism (VTE) risk and atherosclerotic-related complications including myocardial infarction (1).Although…
Abstract Number: 1731 • ACR Convergence 2023
A Competitive Inhibitor of MOART Showed Potent Therapeutic Effects in a Mouse Model of Collagen-induced Arthritis
Sujin Park¹, DongWoo Kang², Haein An¹, Eunji Hong¹, Kwiyeom Yoon², MinWoo Kim², Hwajung Kim² and Seong Jin Kim², ¹GILO Institute, GILO Foundation, Seoul, South Korea, ²Medpacto Inc., Seoul, South Korea
Background/Purpose: Despite tumor necrosis factor (TNF) inhibitors and Jak kinase inhibitors (JKI) have shown a significant advance in the treatment of rheumatoid arthritis (RA) however,…
Abstract Number: 1747 • ACR Convergence 2023
A Newly Described Cytokine interleukin-40 Is Increased in the Serum of Individuals At-risk of Rheumatoid Arthritis and Induces an Inflammatory Response in Mononuclear Cells
Adela Navratilova¹, Klára Prajzlerová², Nora Růžičková³, Karel Pavelka⁴, Jiri Vencovsky⁵, Ladislav Senolt⁶, Maria Filkova³ and Lucie Andrés Cerezo³, ¹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Hlavní město Praha, Czech Republic, ²Institute of Rheumatology, Prague, Czech Republic, ³Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁴Institut of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic, ⁵Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁶Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Praha, Czech Republic
Background/Purpose: Interleukin-40 (IL-40) is a newly described cytokine related to malignancies and immunity function. We have previously shown that IL-40 is up-regulated in early stages…
Abstract Number: 1763 • ACR Convergence 2023
Asthma Severity Is Associated Increased Serum Anti-cyclic Antibody Level at Baseline and in Increase During Longitudinal Follow-up
Drayton Rorah¹, Linh Ngo², Mario Castro², Kristen Demoruelle³ and Scott Matson⁴, ¹University of Kansas Medical Center, Kansas City, KS, ²University of Kansas School of Medicine, Kansas City, KS, ³University of Colorado Anschutz Medical Campus, Aurora, CO, ⁴University of Kansas School of Medicine, Kansas City, MO
Background/Purpose: The lung airways have been implicated in the pathogenesis of RA. RA-associated autoantibodies, including anti-cyclic citrullinated peptide (anti-CCP) antibodies are found to be generated…
Abstract Number: 1847 • ACR Convergence 2023
Influence of Seasonal Changes on Adherence in Rheumatoid Arthritis Patients
Cody Schmidt, Kunal Patel, Samantha Delgado, Guy Cozzi, Elisea Avalos-Reyes, W. Cliff Rutter, Rashmi Grover, Lucia Feczko, Will Cavers and Kjel Johnson, CVS Health, Woonsocket, RI
Background/Purpose: Rheumatoid arthritis (RA) symptoms are suspected to be linked with exposure to colder environments. Previous studies on RA and seasonality have focused on RA…
Abstract Number: 1911 • ACR Convergence 2023
Using the Technology Acceptance Model to Assess Physician Perceptions and Experiences Using the Rheumatoid Arthritis-Patient-Reported Outcomes Dashboard: Mixed-Methods Study
Catherine Nasrallah¹, Cherish Wilson², Alicia Hamblin¹, Lindsay Jacobsohn¹, Cammie Young³, Cammie Young³, Mary Nakamura⁴, Andrew Gross¹, Judith Ashouri¹, Mehrdad Matloubian¹, Jinoos Yazdany¹ and Gabriela Schmajuk², ¹University of California San Francisco, San Francisco, CA, ²UCSF / SFVA, San Francisco, CA, ³University of California San Francisco, Oakland, CA, ⁴UCSF/SFVAHCS, San Francisco, CA
Background/Purpose: Improving shared decision-making using a treat-to-target approach, including the use of patient reported outcomes (PROs), is important to providing high quality care for rheumatoid…
Abstract Number: 2100 • ACR Convergence 2023
Paradoxical Antagonistic Association of Visceral and Subcutaneous Adipose Tissue with Circulating C-Reactive Protein in Rheumatoid Arthritis
Jon Giles and Joan Bathon, Columbia University, New York, NY
Background/Purpose: C-reactive protein (CRP) is used as an indicator of disease activity in people with RA.However, adipose tissue also expresses inflammatory cytokines that induce hepatic…
Abstract Number: 2117 • ACR Convergence 2023
Frailty Is Associated with Mortality in Veterans with Rheumatoid Arthritis
Sayuli Bhide¹, Punyasha Roul², Namrata Singh³, Grant Cannon⁴, Gary Kunkel⁵, Ted R Mikuls⁶, Bryant England², Dolores Shoback⁷, Patti Katz⁸, Jose Garcia⁹, Ariela Orkaby¹⁰, Joshua Baker¹¹ and K Wysham¹², ¹University of Washington, Seattle, WA, ²University of Nebraska Medical Center, Omaha, NE, ³University of Washington, Bellevue, WA, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵University of Utah, Salt Lake City, UT, ⁶Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁷San Francisco VA Medical Center, San Francisco, CA, ⁸University of California San Francisco, San Rafael, CA, ⁹VA Puget Sound Healthcare System, Seattle, WA, ¹⁰Veterans Affairs Boston Healthcare System & Brigham and Women’s Hospital, Harvard Medical School, Boston, MA; VA Geriatric Research Education and Clinical Center, Boston, MA, ¹¹University of Pennsylvania, Philadelphia, PA, ¹²VA Puget Sound/University of Washington, Seattle, WA
Background/Purpose: Frailty is established as an important predictor of mortality in the general population.1Rheumatoid arthritis (RA) is associated with higher rates of frailty than the…
Abstract Number: 2133 • ACR Convergence 2023
Cardiovascular Risk Factors Are Associated with Discontinuation of Advanced Therapies Due to Treatment Failure in Rheumatoid Arthritis: Results from the OBRI
Samar Aboulenain¹, Xiuying Li², Mohammad Movahedi³, Claire Bombardier¹ and Bindee Kuriya¹, ¹University of Toronto, Toronto, ON, Canada, ²Toronto General Hospital, Toronto, ON, Canada, ³Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: Cardiovascular (CVD) comorbidity can impact overall RA care. We demonstrated that CVD risk factors were associated with higher disease activity and disability. Here, we…
Abstract Number: 2149 • ACR Convergence 2023
Biologic IRL201805 Drives Differential Cell-contact and Metabolism Transcriptional Profiles in Monocytes from RA Patients Compared to Healthy Donors
Yuriko Yamamura¹, Kieran Woolcock², Valerie Corrigall³, Lara Ravanetti⁴, Jorge De Alba⁴, Roly Foulkes⁵, Paul Eggleton⁶ and Carl Goodyear², ¹School of Infection & Immunity, University of Glasgow, Glasgow, United Kingdom, ²University of Glasgow, Glasgow, United Kingdom, ³Revolo Biotherapeutics, Tadworth, United Kingdom, ⁴Revolo Biotherapeutics, London, United Kingdom, ⁵Revolo Biotherapeutics, Slough, United Kingdom, ⁶Revolo Biotherapeutics, Exeter, United Kingdom
Background/Purpose: IRL201805 is a novel biologic derived from Binding Immunoglobulin Protein (BiP) that has been developed for the treatment of Rheumatoid arthritis (RA) (P Eggleton,…
Abstract Number: 2166 • ACR Convergence 2023
Long-Term Effects of Abatacept on Arthritis and Atherosclerosis in Older vs Younger Patients with Rheumatoid Arthritis: 3-year Results of a Prospective, Multicenter, Observational Study
Zento Yamada¹, Sei Muraoka¹, Mai Kawazoe², Wataru Hirose³, Hajime Kono⁴, Shinsuke Yasuda⁵, Takahiko Sugihara⁶ and Toshihiro Nanki², ¹Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Ota-ku, Japan, ³Hirose Clinic of Rheumatology, Saitama, Japan, ⁴Teikyo University School of Medicine, Tokyo, Japan, ⁵Department of Rheumatology, Graduate School of Medical and Dental Science, Tokyo Medical and Dental University (TMDU), Tokyo, Japan, ⁶Toho University, Tokyo, Japan
Background/Purpose: Patients with rheumatoid arthritis (RA) are at an increased risk of cardiovascular disease secondary to atherosclerosis. Although it has been reported that TNF inhibitor…
Abstract Number: 2434 • ACR Convergence 2023
Acetylated Bacterial Proteins as Potent Antigens Inducing an Anti-modified Protein Antibody Response
Mikhail Volkov, Arieke Kampstra, Karin van Schie, Joanneke Kwekkeboom, Arnoud de Ru, Peter van Veelen, Thomas Huizinga, René Toes and Diane van der Woude, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Gut-residing bacteria, such as E.coli, can acetylate their proteome under conditions of amine starvation. It is postulated that the (gut) microbiome is involved in…
Abstract Number: 2507 • ACR Convergence 2023
ZCCHC6 Modulates the Global Phosphorylation Landscape in TNF-a-induced Rheumatoid Arthritis Synovial Fibroblasts
Anil Singh, Farheen Sultan Shaikh and Salahuddin Ahmed, Washington State university, Spokane, WA
Background/Purpose: ZCCHC6, also known as TUT7 or TENT2, plays a crucial role in RNA processing and metabolism through its uridylyl transferase function. This function involves…
Abstract Number: 2592 • ACR Convergence 2023
Trends, Sociodemographic and Clinical Factors Associated with Avascular Necrosis and Related Arthroplasties in Hospitalized Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Rashmi Dhital¹, Neha Singh², Brian Pedersen² and Christie M. Bartels³, ¹UC San Diego, San Diego, CA, ²University of California San Diego, San Diego, CA, ³University of Wisconsin, School of Medicine and Public Health, Madison, WI
Background/Purpose: Avascular necrosis (AVN) can be a debilitating complication of autoimmune diseases and steroid treatment, with a higher prevalence in systemic lupus erythematosus (SLE) (0.8-33%)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].